Generic antiretroviral drugs are pivotal in the implementation of WHO's ‘3 by 5’ programme. However, clinical experience with generics in sub-Saharan Africa is insufficiently documented. We report on 50 patients with HIV-associated Kaposi's sarcoma treated with generic fixed-dose highly active antiretroviral therapy. At 52 weeks, 74% achieved an undetectable viral load of < 50 copies/ml, 86% achieved < 400 copies/ml, and a 3.1 log10 decline from baseline. Side-effects were minimal. The outcomes support the use of generic antiretroviral therapy.
Departments of aDermatology
bMolecular Virology and Bioinformatics, Africa Centre for Health and Population Studies, Durban, South Africa
cCentre for HIV/AIDS Networking
dDepartment of Infectious Diseases
eAIDS Programme, Yale University School of Medicine, New Haven, CT, USA
fDepartment of Haematologic Malignancies, MGH Cancer Center, Harvard Medical School, Cambridge, MA, USA
gDepartment of Oncology and Radiotherapy
hMedical Bioethics Unit
iVictor Daitz Chair of HIV/AIDS Research, Faculty of Health Sciences, Nelson R. Mandela School of Medicine, University of KwaZulu, Natal, South Africa.
Received 25 November, 2004
Accepted 23 December, 2004